Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

buprenorphine

Sanofi reception

Lilly and Boehringer launch first Lantus clone Basaglar in US

Starts biosimilar at 15% discount to Sanofi’s basal insulin product

- PMLiVE

FDA green light for Pfizer’s eczema drug

Blockbuster-hopeful Eucrisa expected to launch early next year at $580 per 60mg tube

Bristol-Myers Squibb (BMS) building

BMS restructures US R&D operations

Unveils site closures and build plans as firm focuses pipeline around three US hubs

- PMLiVE

After Senate vote, Cures Act is en route to Obama for signature

Set to accelerate access to new therapies through real-world data and surrogate efficiency measures

- PMLiVE

Global drug spending will rise by a third to $1.5trn in 2021

However, rate of growth will not match previous years due to pricing and access pressures

- PMLiVE

FDA starts speedy review of Merck/Pfizer’s PD-L1 inhibitor

If approved avelumab would be first approved cancer immunotherapy for metastatic MCC

- PMLiVE

Shire to focus rare disease R&D with new US facility

Cambridge, Massachusetts hub to drive firm’s push to become leading rare disease specialist

- PMLiVE

McCann Health and Langland lead Global Awards 2016 winners

Collect best global network and best agency awards for fifth consecutive year

Sanofi reception

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out

AstraZeneca AZ

Trials of AZ’s durvalumab restart as FDA hold is relaxed

Bleeding side effects in two head and neck cancer studies not attributed to the PD-L1 inhibitor

- PMLiVE

GSK files first application for triple COPD therapy

Submits combo in the US one year early to coincide with EU marketing application

Novartis building

Novartis gets speedy FDA review for midostaurin

Leukaemia treatment could become first targeted therapy for 25 years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links